Company Overview
Snapshot
Founded in May 2012 by Rafi Herzog, AlphaMet operates with 1–10 employees. The company has raised $820,000 across 3 funding rounds from 1 investor. In February 2020, AlphaMet secured funding from PipelBiz.
Business overview
AlphaMet, formerly known as Cycla Orthopedics, develops, manufactures, and markets the CyclaPlex Correction System. This implant device is designed to prevent bone osteotomy, shorten recovery time, and reduce pain for patients undergoing bunion surgery. The company operates within the Health Tech & Life Sciences sector, specifically focusing on medical devices and medical treatment & therapeutics, serving healthcare providers.
Strategic signal
In February 2017, AlphaMet announced its intention to expand the global reach of its bunion treatment solutions. This signals the company's strategic focus on international market penetration for its FDA-cleared CyclaPlex Correction System, indicating a drive for broader commercial adoption and impact within the orthopedic medical device industry.
Log in to access full profile ›Company Intelligence Q&A
- When was AlphaMet founded?
- AlphaMet was founded in May 2012 by Rafi Herzog.
- What is AlphaMet's primary product?
- AlphaMet's primary product is the CyclaPlex Correction System, an implant device designed for bunion surgery to prevent bone osteotomy, shorten recovery time, and reduce pain.
- What was a significant development for AlphaMet in February 2017?
- In February 2017, AlphaMet announced its intention to treat bunions worldwide, indicating a strategic focus on global market expansion for its medical device.
- Has AlphaMet received any funding?
- AlphaMet has raised a total of $820,000 across three funding rounds. In February 2020, the company secured funding from PipelBiz.
- What is the regulatory status of the CyclaPlex Correction System?
- The CyclaPlex Correction System is FDA cleared for use by surgeons.